Top 5 Medical Technology

Top 5 Medical Technology Innovations

With the growing technology around the world, each sector is taking full advantage to streamline their services and growth to the very best. Medical industry is no exception in that case. Today’s medical technology innovations have been focusing on the faster, cheaper and deliver efficient patient care. At present, Health care technology is necessary to ensure to deliver sufficient healthcare service, cut down costs, save many lives and provide significant benefits to the patients.

Below are the top five medical technology innovations that are really beneficial to the lives of the human beings:



1. Cutting back on Melanoma Biopsies (The Mela Find technology)



Melanoma are very large number of moles which are dangerous at their sight but actually harmless. Those moles have long been confused with skin cancer and flooded patients in hospital. The purpose of the new technology is to control these kind of patients by cutting down on cost of service delivery and creating time and space for medical practitioners to attend to more urgent activities rather than attending to those melanoma patients. It has only been possible to identify these moles through an invasive surgical biopsy.

There is a new handheld tool which is a Mela find scanner that analyses the tissue morphology. lt helps to determine when to order for a surgical biopsy and eliminates unnecessary surgery. It uses the missile navigation technologies. On its application, the suspected surfaces of the skin are scanned by optic lenses at a ten electromagnetic wavelengths. Signals are investigated by matching them against 10,000 digital images of melanoma and skin cancer diseases. With this knowledge, biopsy scars are not harmful and not necessary to admit a patient into the hospital.



2. 3D Printed Biological Materials



 3D printers have been invented in many areas with no exception in the healthcare industry. It is a technology that has given these industry hopes of finally reviving the many unsolved problems concerning healthcare. It is with the best interest to spread the application to improve the quality of service being delivered and the standards of human life. If below tools are used, they may bring rampant growth and benefits;



Printing skin
With the addition of lensor-printed skin cells, this innovation helps to prevent flocking patients with unnecessary claims of a skin disease and will ban these victims.



Embryonic Stem cells
Their main purpose is to help in growth of new organs, creating tissues and for testing drugs. One step has already been taken that involved printing these cells in the lab and has successfully been done.



Blood vessels and heart tissues
These have involved laboratory invention of a heart that operates normally like real heart. It has been invented by Organova Company by printing sheets of cardiac tissue and blood vessels.



Studying cancer
These have been done by printing cancer cells in the lab with the objective of studying cancer cells, testing cancer drugs and to eventually find a cure. These cells are grown on a tissue in the lab.
Replacing cartilage and bone
Scientists have printed stem cells that will grow into a bone and cartilage. These will in turn create their availability to put in patients that need them. The aim is to replace the organ donation and save the lives lost due to the delayed donation.



3. Electronic Aspirin



Migraines, severe headaches, facial pain and other causes of chronic pain has always been associated with sphenopalatine ganglion (SPG), which is a facial nerve bundle. Doctors have always been prescribing drugs on these patients to lower the risk, relieve the pain but do not completely eliminate it and victims suffer long enough not knowing what to opt for. This new technology will help prevent the ailments and bring safety to patients. It blocks the SPG signal whenever there is a sign of headache.

 Application involves implanting permanently a small nerve stimulating device at the side of the head in the upper gum normally affected by headache. Also involves handheld remote control which places on the cheek near the implant whenever the patient senses onset of a headache. The implant is designed with a lead that connects the SPG bundle at the tip. On the placement of the remote controller, a signal is stimulated which blocks the pain and for a short moment the feeling of headache goes. The implant is very adaptable in everyday life and doesn’t prevent the user from normal living.



4. Hybrid operating room



Hybrid operating room is a surgical theatre that is equipped with the advanced medical technology innovations such as fixed C-arm scanners, CT scanners and MRI scanners. An example of the hybrid operating room is the Lake Reginal Media Center which indicates how operation rooms have grown up to enable efficient service delivery and developed medical equipment.

Hybrid operating room is an innovation that will enable fast growth in the industry and eliminate delays of the approved technologies. This is because, as new technologies are increasingly flooding and replacement of new ones needed with urgency, the advanced outfit will enhance quick administration of these innovations.

To the patients, it has increasingly reduced trauma, fear and too long operations. The technology has enhanced performance of high risk cardiac procedures and real time intra operative image guidance. Generally it has improved patients experience and effective service delivery by medical professionals.
5. Needle free diabetes care



The new technology in being developed by Echo Therapeutics Company to replace skin pricking and poking with just a pack. Diabetes self-care has always been painful and exposing one to infections. Patients have been using daily sugar level checks by continuously drawing blood to measure sugar level and administering daily insulin shots to regulate it. It’s very involving and sometimes stressful too. Alternatively, they have been using glucose monitors and insulin pumps, which is a very complicated repetitive procedure for managing blood sugar that still do not completely eliminate skin shots and pricks.

With the new technology, the patient’s safety will be enhanced. The company aims to come up with a transdermal biosensor that will read and analyze skin without drawing blood. The main equipment is handheld electric device resembling a toothbrush that removes the top layer cells of the skin for examination. The patient’s blood will then be analyzed within a signal range of a patch —bone biosensor. The readings are collected at a one minute interval by the sensor which is send to a remote monitor by a wireless connection .When sugar level go out of the patient’s optimal range, it triggers audible alarms. This will help to regulate the blood sugar level within the set range.

These are the top five medical technology innovations that enhances the life and comfort ness of the human beings and improves the treatment levels. Apart from that it is also important for the individuals to remember that healthy life style is crucial for the well-being of the individuals.

  

List of DRUGS Banned For Marketing In India

LIST OF DRUGS BANNED FOR MARKETING IN INDIA

The Government of India vide notifications published in the Gazette of India vide G.S.R. No. 578 (E) dated 23/07/1983 and subsequent amendments, made under Section 26 A of Drugs and Cosmetics Act, 1940 has prohibited the manufacture, sale and distribution of the following categories of fixed dose combinations which do not have any therapeutic justification or are likely to involve risk to human beings:

G.S.R. No. 578 (E) dt 23-07-1983
1. Amidopyrine.
2. Fixed dose combinations of vitamins with anti-inflammatory agents and tranquilizers.
3. Fixed dose combinations of Atropine and Analgesic and Antipyretics.
4. Fixed dose combinations of Strychnine and Caffeine in tonics.
5. Fixed dose combinations of Yohimbine and Strychnine with Testosterone and Vitamins.
6. Fixed dose combinations of Iron with Strychnine, Arsenic and Yohimbine.
7. Fixed dose combinations of Sodium Bromide/chloral hydrate with other drugs.
8. Phenacetin.
9. Fixed dose combinations of antihistaminic with anti-diarrhoeals.
10. Fixed dose combinations of Penicillin with Sulphonamides.
11. Fixed dose combinations of Vitamins with Analgesics.
12. Fixed dose combinations of Tetracycline with Vitamin C.

G.S.R. No. 793 (E) dt 13-12-1995
13. Fixed dose combinations of Hydroxyquinoline group of drugs with any other drug except for preparations meant for external use only.

G.S.R. No. 1057 (E) dt 03-11-1988
14. Fixed dose combinations of Corticosteroid with any other drug for internal use except for preparations meant for meter dose inhalers and dry powder inhalers.[Substituted vide GSR 738 (E) dated 9.10.2009]
15. Fixed dose combinations of Chloramphenicol with any other drug for internal use.

G.S.R. No. 304 (E) dt 07-06-1991
16. Fixed dose combinations of crude Ergot preparation except those containing  Ergotamine, Caffeine, analgesics, antihistamines for the treatment of migraine, headache.
G.S.R. No. 578 (E) dt 23-07-1983
17. Fixed dose combinations of Vitamins with Anti TB drugs except combination of Isoniazid with Pyridoxine Hydrochloride (Vitamin B6).
18. Penicillin skin/eye Ointment.
19. Tetracycline Liquid Oral preparations.
20. Nialamide.
21. Practolol.
22. Methapyrilene, its salts.
G.S.R. No. 49 (E) dt 31-01-1984
23. Methaqualone.

G.S.R. No. 322 (E) dt 03-05-1984
24. Oxytetracycline Liquid Oral preparations.
25. Demeclocycline Liquid Oral preparations.

G.S.R. No. 863 (E) dt 22-11-1985
26. Combination of Anabolic Steroids with other drugs.
G.S.R. No. 743 (E) dt 10-08-1989
27. Fixed dose combination of Oestrogen and Progestin (other than oral contraceptives) containing per tablet Estrogen content of more than 50 mcg (equivalent to Ethinyl Estradiol) and Progestin content of more than 3 mg (equivalent to Norethisterone Acetate) and all fixed dose combination injectable preparations containing synthetic Oestrogen and Progesterone. (Subs. By Noti. No. 743 (E) dt 10-08-1989)

G.S.R. No. 999 (E) dt 26-12-1990
28. Fixed dose combinations of Sedatives/ hypnotics/anxiolytics with analgesics-antipyretics.
G.S.R 100 (E) dt 11-02-2003 (with effect from 11-02-2003)
29. Fixed dose combination of Rifampicin, Isoniazid and Pyrazinamide, except those which provide daily adult dose given below: -

             Drugs              Minimum             Maximum                                
             Rifampicin       450  mg                600 mg                                    
             Isoniazid         300  mg              400  mg                                    
             Pyrazinamide 1000 mg              1500  mg”

G.S.R. No. 999 (E) dt 26-12-1990
30. Fixed dose combination of Histamine H-2 receptor antagonists with antacids except for those combinations approved by Drugs Controller, India.
31. The patent and proprietary medicines of fixed dose combinations of essential oils with alcohol having percentage higher than 20% proof except preparations given in thein the Indian Pharmacopoeia.
32. All Pharmaceutical preparations containing Chloroform exceeding 0.5% w/w or v/v whichever is appropriate.

G.S.R. No. 69 (E) dt 11-02-1991
33. Fixed dose combination of Ethambutol with INH other than the following: INH Ethambutol 200 mg. 600 mg. 300 mg. 800 mg.
34. Fixed dose combination containing more than one antihistamine.
35. Fixed dose combination of anthelmintic with cathartic/purgative except for piperazine.

Substituted vide G.S.R 290 (E) dt 16-04-2008
36. Fixed dose combination of Salbutamol or any other bronchodilator with centrally acting anti-tussive and/or antihistamine.

G.S.R. No. 69 (E) dt 11-02-1991
37. Fixed dose combination of laxatives and/or anti-spasmodic drugs in enzyme preparations.
Substituted vide G.S.R 603 (E) dt 24-08-2001 (with effect from 01-09-2002)
38. Fixed dose combination of Metoclopramide with other drugs except combination of Metoclopramide with Aspirin/ Paracetamol with effect from 1st September, 2002.
G.S.R. No. 69 (E) dt 11-02-1991
39. Fixed dose combination of centrally acting, antitussive with antihistamine, having atropine like activity in expectorants.
40. Preparations claiming to combat cough associated with asthma containing centrally acting antitussive and/ or an antihistamine.
41. Liquid oral tonic preparations containing glycerophosphates and/or other phosphates and / or central nervous system stimulant and such preparations containing alcohol more than 20% proof.
42. Fixed dose combination containing Pectin and/or Kaolin with any drug which is systemically absorbed from GI tract except for combination of Pectin and/or Kaolin with drugs not systemically absorbed.

G.S.R. No. 304 (E) dt 07-06-1991
43. Chloral Hydrate as a drug.

G.S.R. No. 612 (E) dt 09-08-1994
44. Dovers Powder I.P.
45. Dover's Powder Tablets I.P.

G.S.R. No. 731 (E) dt 30-09-1994
46. Antidiarrhoeal formulations containing Kaolin or Pectin or Attapulgite or Activated Charcoal.
47. Antidiarrhoeal formulations containing Phthalyl Sulphathiazole or Sulphaguanidine or Succinyl Sulphathiazole.
48. Antidiarrhoeal formulations containing Neomycin or Streptomycin or Dihydrostreptomycin including their respective salts or esters.
49. Liquid Oral antidiarrhoeals or any other dosage form for pediatric use containing Diphenoxylate or Atropine or Belladona including their salts or esters or metabolites Hyoscyamine or their extracts or their alkaloids.
50. Liquid Oral antidiarrhoeals or any other dosage form for pediatric use containing halogenated hydroxyquinolines.
51. Fixed dose combination of antidiarrhoeals with electrolytes.

G.S.R. No. 57 (E) dt 07-02-1995
52. Patent and Proprietary Oral Rehydration Salts other than those conforming to the following parameters:
      (a) Patent and Proprietary Oral Rehydration Salts on reconstitution to one litre shall contain:- Sodium - 50 to 90 millimoles. Total osmolarity - 240 - 290 milli osmoles. Dextrose : Sodium molar ratio - Not less than 1:1 and not more than 3:1
      (b) Patent and Proprietary cereal based Oral Rehydration Salts on reconstitution to one litre shall contain :- Total osmolarity - Not more than 2900 milli osmoles. Precooked rice- Equivalent to not less than 50 gm and not more than 80 gm as total replacement of Dextrose.
      (c) Patent and Proprietary Oral Rehydration Salts (ORS) may contain aminoacids in addition to Oral Rehydration Salt conforming to the parameters specified above and labeled with the indication for "Adult Choleratic Diarrhoea" only.
      (d) Patent and Proprietary Oral Rehydration Salts shall not contain Mono or Polysaccharides or saccharin sweetening agent.
G.S.R. No. 633 (E) dt 30-09-1995, GSR No. 123 (E) dt 11-03-1996 and GSR No. 230 (E) dt 04-06-1996
53. Fixed dose combination of Oxyphenbutazone or Phenylbutazone with any other drug.
54. Fixed dose combination of Analgin with any other drug. [Words "other than antispasmodics"omitted vide G.S.R. No. 405 (E) dt 03-06-1996]

    Clarification: Fixed dosecombination of Analgin with any other drug other than antispasmodics were banned by the Government of India vide G.S.R. No. 633(E), dated 13.09.1995. However, the Drug Action Forum contended before the Supreme Court that the preparations of Analgin and antispasmodics should also be banned. Dr. J.S. Bajaj, being directed by the court, submitted his report supporting these contentions.

     On 17th Dec. 1996, a learned additional Solicitor submitted that the Central Government has decided that all State/U.T. Drug Licensing Authorities will be given directions by the Government under Section 33-P of the Drugs and Cosmetics Act, to suspend manufacturing licenses of all fixed dose formulations of Analgin including Analgin with Antispasmodics till further notice. Accordingly, the Government of India, under letter dated 17th Dec.1996, issued such directives. In view of the above directives, the manufacture, sale and distribution of fixed dose combinations of Analgin and antispasmodics is prohibited.

55. Fixed dose combination of dextropropoxyphene with any other drug other than anti-spasmodics and/or non-steriodal anti-inflammatory drugs (NSAIDS).
56. Fixed dose combination of a drug, standards of which are prescribed in the Second Schedule to the said Act with an Ayurvedic, Siddha or Unani drug.

G.S.R. No. 93 (E) dt 25-02-1997
57. Parenteral preparations containing fixed dose combination of streptomycin with penicillins with effect from 01-01-1998.

G.S.R. No. 499 (E) dt 14-08-1998
57. Mepacrine Hydrochloride (Quinacrine and its salts) in any dosage form for use for female sterilization or contraception.
58. Fenfluramine and Dexfenfluramine.
[59. Fixed dose combination of haemoglobin in any form (natural or synthetic).
60. Fixed dose combination of Pancreatin and Pancrelipase containing amylase, protease, and lipase with any other enzyme.
(Both 59 & 60 added by G.S.R. 590 (E) dt. 17-8-1999.
Sr. No. 59 & 60 omitted by G.S.R. 704(E) dt. 20-10-1999.)]
G.S.R. No. 169 (E) dt 12-03-2001
59. Fixed dose combination of Diazepam and Diphenhydramine Hydrochloride.
G.S.R. No. 885  (E) dt 11-12-2009 (with effect from 11-12-2009)
60. Rimonabant.
G.S.R. No. 702 (E) dt 20-10-1999 (with effect from 1-1-2001)
61. Fixed dose combination of Vitamin B1, Vitamin B6 and Vitamin B12 for human use with effect from 01-01-2001

G.S.R. No. 814 (E) dt 16-12-1999 (w.e.f. 01-09-2000)
62. Fixed dose combination of haemoglobin in any form (natural or synthetic).
63. Fixed dose combination of Pancreatin and Pancrelipase containing amylase, protease and lipase with any other enzyme.
G.S.R. No. 170 (E) dt 12-03-2001 (with effect from 01-01-2002)
64. Fixed dose combination of Nitrofurantoin and trimethoprim.
65. Fixed dose combination of Phenobarbitone with any anti-asthmatic drug.
66. Fixed dose combination of Phenobarbitone with Hyoscin and/or Hyoscyamine.
67. Fixed dose combination of Phenobarbitone with Ergotamine and/or Belladona.
68. Fixed dose combination of Haloperidol with any anti-cholinergic agent including Propantheline Bromide.
69. Fixed dose combination of Nalidixic Acid with any anti-amoebic including Metronidazole.
70. Fixed dose combination of Loperamide Hydrochloride with Furazolidone.
71. Fixed dose combination of Cyproheptadine with Lysine or Peptone.
G.S.R 603 (E) dt 13-08-2001 (with effect from 01-09-2002)
72. Fixed dose combination of Metoclopramide with other drugs except combination of Metoclopramide with Aspirin/ Paracetamol with effect from 1st September, 2002.
G.S.R. No. 732 (E) dt 29-10.2002, Amended vide GSR 191(E) dt 05-03-2003 (with effect from 01-08-2003)
73. Astemizole
74. Terfinadine
G.S.R 100 (E) dt 11-02-2003 (with effect from 11-02-2003)
75. Fixed dose combination of Rifampicin, Isoniazid and Pyrazinamide, except those which provide daily adult dose given below: -

             Drugs              Minimum             Maximum                                
             Rifampicin       450  mg                600 mg      
   g                                    
             Isoniazid         300  mg               400  mg                                    
             Pyrazinamide 1000 mg              1500  mg”
G.S.R. No. 780 (E) dt 01-10-2003 (with effect from 01-10-2003)
76. Phenformin for human use.
G.S.R. No. 810 (E) dt 13-12-2004 (with effect from 13-12-2004)
77. Rofecoxib and its formulations for human use.
G.S.R. No. 510 (E) dt 25-7-2005 (with effect from 25-7-2005)
78. Valdecoxib and its formulations for human use.
G.S.R. No. 499 (E) dt 4-7-2008 (with effect from 5-7-2008)
79. Diclofenac and its formulations for animal use.
G.S.R. No. 910 (E) dt 12-11-2010 (with effect from 12-11-2010)
80. Rosiglitazone and its formulations for human use.
G.S.R. No. 82 (E) dt 10-2-2011 (with effect from 10-2-2011)
81. Nimesulide formulations for human use in children below 12 years of age.
82. Cisapride and its formulations for human use.
83. Phenylpropanolamine and its formulations for human use,*
84. Human Placental Extract and its formulations for human use except its,  
      (i) Topical application for wound healing, and  (ii) Injection for pelvic inflammatory disease (Substituted vide G.S.R. No. 418 (E) dt 30-5-2011 (with effect from    30-5-2011)
85. Sibutramine and its formulations for human use, and
86. R-Sibutramine and its formulations for human use.
G.S.R. No. 218 (E) dt 16-3-2011 (with effect from 16-3-2011)
87. Gatifloxacin formulation for systemic use in human by any route including oral and injectable; and
88. Tegaserod and its formulations for human use.
G.S.R. No. 752 (E) dt 12-10-2011 (with effect from 12-10-2011)
89.Letrozole for induction of ovulation in anovulatory infertility.
G.S.R. No. 432 (E) dt 7-6-2012 (with effect from 7-6-2012)
90. Serodiagnostic test kits for diagnosis of tuberculosis.
G.S.R. No. 332 (E) dt 23-5-2013 (with effect from 23-5-2013)
91.[Dextropropoxyphene]¢ and formulations containing Dextropropoxyphene for human use.
G.S.R. No. 377 (E) dt 18-6-2013 (with effect from 18-6-2013) (Quashed in WP Nos 28354/2013 c/w 32766-32768/2013 Lundbeck India Pvt Ltd v. UOI and others, High Court of Karnataka, D/d 14.8.2013)
92. Fixed dose combination of Flupenthixol+Melitracen for human use.
G.S.R. No. 378 (E) dt 18-6-2013 (with effect from 18-6-2013)
93. Analgin and all formulations containing Analgin for human use.
G.S.R. No. 379 (E) dt 18-6-2013 (with effect from 18-6-2013) [G.S.R. No. 520 (E) dt 31-7-2013 revoked the notification with certain conditions]
94. Pioglitazone and all formulations containing Pioglitazone for human use.
In addition to the above-mentioned drugs, manufacture and sale of all Cosmetics and all Ayurvedic Drugs licensed as toothpaste, tooth powders containing tobacco have been prohibited under G.S.R. 443 (E) and 444(E) dated 30.4.92
*Presently stayed by the Hon'ble High Court of Madras
¢Corrected wide GSR 590 (E) dtd 30.8.2013